Dow's Merck Failed On Alzheimer Drug But It Shouldn't Hurt Biogen

Analysts weren't surprised Wednesday after Dow's Merck (MRK) terminated a late-stage study of a potential Alzheimer's disease drug and argued that it won't have implications for Biogen's (BIIB) rival drug.

X The study tested a drug called verubecestat in patients with early-stage Alzheimer's disease. Verubecestat belongs to a class of drugs called BACE inhibitors which aim to prevent the buildup of amyloid plaques in the brain associated with Alzheimer's.

Merck halted a late-stage trial of...

What feeling does this article give you?

#hashtags to follow:

Dow [+]    Merck [+]    MRK [+]    Alzheimer [+]    Biogen [+]    BIIB [+]    BACE [+]   

More #news: